The U.S. FDA approved Genentech’s Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for treating women with advanced ovarian cancer following initial surgical resection.
Marci Piasecki, an industry veteran with more than 30 years of healthcare advertising experience, joined Evoke Health as a member of the agency’s executive leadership team.
DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.
Fingerpaint, an independent, full-service, nationwide marketing agency, closed on the previously announced purchase of its office space at 395 Broadway in downtown Saratoga Springs, NY, from Myron M. Hunt Inc.
Privately held marketing agency Intouch Solutions announced the promotion of five employees in its Kansas City office.
Greater Than One announced that William T. Major joined the agency’s senior leadership team as Director of Operational Excellence.
Amgen today announced that the European Commission approved a new indication for Prolia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Emboldened by 2017’s back-to-back FDA approvals of the first drugs that use genetically engineered patient immune cells – Kymriah (tisagenlecleucel) to treat leukemia and Yescarta (axicabtagene ciloleucel) to combat large-B-cell lymphomas – immunotherapy researchers are continuing to revolutionizing cancer treatment. But uneven patient response rates and the side effects often associated with immunotherapies are putting high priority on accurately identifying which patients would benefit most from particular treatment options.
